🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 60% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
120 Servings
Other Combinations Product Type
60% Evidence Coverage

Supplement Facts — Evidence Check

7.5 mcg (9% DV)
✅ Within RDA (0.1× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.0075mg
Calcium
125 mg (13% DV)
60 mg (6% DV)
✅ Within RDA (0.1× RDA of 700 mg) 📚 12 studies (Tier A: 0, B: 3)
RDA 700mg This product: 60mg UL 4000mg
125 mg (31% DV)
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 125mg
0.25 mg
📊 Market median: 3.0mg (58 products) 📚 2 studies — no high-quality reviews
This product: 0.25mg UL 20mg

Other Ingredients

Cellulose modified Cellulose Gum Vegetable Stearine Magnesium Stearate Silica

Label Claims — Verification

Nutrient
All Other
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Usage: As a dietary supplement, adults take 1 to 8 tablets daily or as directed by your healthcare professional.

⚠️ Warnings & Precautions

WARNING: This product contains Vitamin K, which interferes with the prescription drugs Coumadin(R) and Warfarin. If you are taking these or similar prescription drugs, consult your healthcare professional before using this product.

Tamper resistant package, do not use if outer seal is missing.

KEEP OUT OF REACH OF CHILDREN.

🧪 Formulation Notes

Osteo-Guard(R) One-To-One, prepared from young bovine bone, provides calcium and phosphorus (as microcrystalline hydroxyapatite), trace minerals, bone matrix proteins, amino acids and glycosaminoglycans in their natural forms and physiologic ratios found in whole bone. Magnesium is included in an equal amount to calcium, providing a calcium to magnesium ratio of one-to-one (1:1).

Additional Information

For optimal storage conditions, store in a cool, dry place. (59(0) - 77(0)F/15(0) - 25(0)C) (35-65% relative humidity)

OSG1

Product Details

UPC / SKU 7 45287 04012 6
DSLD Entry Date 2012-10-01
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 10984
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →